A Phase 1 interventional study of Belantamab mafodotin in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 28th largest by enrollment, is one of 6 that started in 2020, is one of 11 in phase 1, reaches primary completion later than 8 of the 34 other live ones, and was the 9th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 22nd largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2020, is one of 12 in phase 1, reaches primary completion later than 6 of the 19 other live ones, and was the 22nd registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two parts: part 1 will include participants with normal/mildly impaired renal function and severe renal impairment and part 2 will include participants with end-stage renal disease (ESRD), where participants are either not undergoing or require hemodialysis. Participants will be administered belantamab mafodotin at a dose of 2.5 milligram per kilogram (mg/kg) intravenously once in three weeks (Q3W) dosing in Part 1. Based on the Part 1 Safety/Pharmacokinetic (PK) data, Part 2 participants will be administered the dose of either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose). Participants will be treated with belantamab mafodotin monotherapy until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. This study will include a screening phase, treatment phase, follow-up phase and a post analysis continued treatment (PACT) phase . The total duration of the study is approximately up to 48 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal or mildly impaired renal function (Normal: individual glomerular filtration rate \[iGFR\]: \>=90 milliliter per minute; Mild impairment: iGFR: 60-89 mL/min will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
Drug: Belantamab mafodotin
Participants with severely impaired renal function (iGFR: 15-29 mL/min) will be administered with belantamab mafodotin 2.5 mg/kg as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first.
Drug: Belantamab mafodotin
Participants with ESRD (iGFR: \<15 mL/min) not on dialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21- day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
Drug: Belantamab mafodotin
Participants with ESRD (iGFR: \<15 mL/min) on hemodialysis will be administered with belantamab mafodotin either 2.5 mg/kg or 1.9 mg/kg (or other adjusted dose) as an intravenous infusion over 30 minutes Q3W on Day 1 of every 21-day cycle until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or end of study, whichever occurs first. In Part 2, the dose will be decided after evaluation of pharmacokinetic and safety data of Part 1.
Drug: Belantamab mafodotin
Belantamab mafodotin will be provided as lyophilized powder which will be available as 100 milligrams per vial (mg/vial) in single-use vial for reconstitution. Lyophilized belantamab mafodotin will reconstituted using water for injection, dilute with normal 0.9 % saline before use.
Also known as: GSK2857916
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
Time frame: End of infusion on C1D1 and C3D1
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
Time frame: End of infusion on C1D1 and C3D1
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin total antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
Time frame: End of infusion on C1D1 and C3D1
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
Time frame: End of infusion on C1D1 and C3D1
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
Time frame: End of infusion on C1D1 and C3D1
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
Time frame: End of infusion on C1D1 and C3D1
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Time frame: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
Time frame: Baseline (Day 1) and up to approx. 236 weeks
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Heart Rate
Heart rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and up to approx. 236 weeks
Part 1 and Part 2: Number of Participants With Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 236 weeks
Part 1 and Part 2: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Baseline (Day 1) and up to approx. 236 weeks
Part 1 and Part 2: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Baseline (Day 1) and up to approx. 236 weeks
Part 1 and Part 2: Change From Baseline (CFB) in Weight
Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline
Time frame: Baseline (Day 1) and up to approx. 236 weeks
Part 1 and Part 2: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess occult blood and protein in urine by dipstick method. Data is presented as "No Change/Decreased" and "Any Increase" that includes Increase to TRACE, Increase to 1+, Increase to 2+ and Increase to 3+ indicating proportional concentrations in the urine sample. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
Time frame: Baseline (Day 1) and up to approx. 236 weeks
| Milestone | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Started | 10 | 9 | 4 | 5 | 8 |
| Safety population | 10 | 9 | 4 | 5 | 8 |
| Pharmacokinetic (pk) evaluable population | 8 | 8 | 0 | 5 | 8 |
| Completed | 8 | 7 | 1 | 3 | 4 |
| Not completed | 2 | 2 | 3 | 2 | 4 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 | 0 | 1 |
| Withdrew: Ongoing at time of analysis | 0 | 0 | 1 | 2 | 3 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
| hour*microgram/millitre(h*ug/mL) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 4021.3 ± 54.3 | 3704.7 ± 32.4 |
| Cycle 3 | 6729.9 ± 32.1 | 4127.8 ± 30.4 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 4379.2 ± 32.4 | 3683.1 ± 32.6 |
| Cycle 3 | 7245.1 ± 42.2 | 3731.4 ± 17.8 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 Day 1 | 54.43 ± 31.5 | 45.66 ± 20.8 |
| Cycle 3 Day 1 | 48.07 ± 39.4 | 32.70 ± 39.8 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 62.01 ± 38.4 | 47.62 ± 24.8 |
| Cycle 3 | 74.18 ± 15.9 | 42.17 ± 58.0 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 1.508 (0.650 to 2.083) | 3.000 (0.667 to 7.400) |
| Cycle 3 | 4.000 (2.000 to 8.000) | 2.083 (0.700 to 4.017) |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 1.954 ± 63.8 | 2.178 ± 39.9 |
| Cycle 3 | 3.109 ± 34.1 | 3.011 ± 22.3 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 396.3 (163.0 to 579.9) | 506.4 (503.3 to 528.4) |
| Cycle 3 | 501.3 (334.8 to 697.7) | 482.5 (335.4 to 505.2) |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 5591.2 ± 76.4 | 5443.7 ± 27.4 |
| Cycle 3 | 9240.4 ± 18.9 | 7579.4 ± 35.1 |
Blood samples were collected for PK analysis of belantamab mafodotin total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 6543.6 ± 69.0 | 5217.0 ± 28.4 |
| Cycle 3 | 9615.3 ± 19.0 | 7056.8 ± 32.9 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 Day 1 | 46.72 ± 35.0 | 29.61 ± 71.4 |
| Cycle 3 Day 1 | 54.02 ± 15.1 | 36.83 ± 37.1 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 49.49 ± 30.3 | 39.33 ± 33.6 |
| Cycle 3 | 54.63 ± 14.9 | 38.25 ± 32.0 |
Blood samples were collected for PK analysis of belantamab mafodotin total antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 2.050 (0.583 to 4.067) | 2.008 (0.467 to 7.000) |
| Cycle 3 | 0.667 (0.650 to 2.000) | 2.017 (0.633 to 4.083) |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 8.785 ± 185.8 | 6.489 ± 103.2 |
| Cycle 3 | 7.974 ± 22.8 | 9.359 ± 47.2 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 346.9 (23.7 to 579.9) | 505.5 (334.3 to 528.4) |
| Cycle 3 | 501.3 (334.8 to 697.7) | 482.5 (335.4 to 505.2) |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ng/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 127.3 ± 81.3 | 77.1 ± 53.1 |
| Cycle 3 | 72.8 ± 21.8 | 40.8 ± 178.7 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.
| h*ng/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 134.7 ± 99.8 | 75.2 ± 48.2 |
| Cycle 3 | 61.2 ± 6.0 | 79.6 ± 39.3 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
| ng/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 Day 1 | 0.84 ± 61.4 | 0.41 ± 78.2 |
| Cycle 3 Day 1 | 0.54 ± 83.1 | 0.32 ± 174.1 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ng/mL | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 1.63 ± 64.0 | 0.71 ± 48.2 |
| Cycle 3 | 0.74 ± 19.2 | 0.50 ± 100.6 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 16.017 (0.917 to 92.600) | 23.400 (7.400 to 30.700) |
| Cycle 3 | 8.000 (0.583 to 22.167) | 23.967 (0.600 to 72.583) |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) |
|---|---|---|
| Cycle 1 | 190.6 (163.0 to 359.5) | 167.7 (166.6 to 334.3) |
| Cycle 3 | 334.8 (144.0 to 358.3) | 167.4 (45.7 to 335.4) |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 4077.6 ± 19.7 | 3065.6 ± 66.2 |
| Cycle 3 | 5773.6 ± 18.8 | 4798.2 ± 56.2 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 3998.5 ± 18.4 | 3717.5 ± 61.3 |
| Cycle 3 | 5764.2 ± 19.2 | 5633.7 ± 40.0 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 Day 1 | 62.81 ± 64.5 | 40.30 ± 38.3 |
| Cycle 3 Day 1 | 61.28 ± 37.4 | 46.38 ± 37.7 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 74.35 ± 50.6 | 53.50 ± 44.9 |
| Cycle 3 | 66.61 ± 36.2 | 48.67 ± 33.8 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 1.833 (0.683 to 4.083) | 1.958 (0.683 to 4.000) |
| Cycle 3 | 1.417 (0.500 to 2.117) | 2.050 (0.633 to 7.833) |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 1.756 ± 73.4 | 2.209 ± 104.4 |
| Cycle 3 | 3.610 ± 54.8 | 2.530 ± 99.0 |
Blood samples were collected for PK analysis of belantamab mafodotin ADC. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 551.3 (503.4 to 689.5) | 505.6 (72.3 to 720.7) |
| Cycle 3 | 502.6 (500.6 to 529.4) | 503.0 (213.4 to 528.3) |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 7099.5 ± 33.4 | 4018.0 ± 86.3 |
| Cycle 3 | 9675.8 ± 8.1 | 8551.8 ± 79.0 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 6798.4 ± 29.2 | 4798.2 ± 65.3 |
| Cycle 3 | 9438.0 ± 9.0 | 10318.8 ± 63.8 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 Day 1 | 62.44 ± 53.0 | 37.24 ± 40.8 |
| Cycle 3 Day 1 | 61.26 ± 41.1 | 38.80 ± 35.7 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 70.96 ± 46.7 | 41.11 ± 44.5 |
| Cycle 3 | 70.67 ± 41.8 | 42.83 ± 40.4 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 1.833 (0.667 to 2.050) | 2.025 (0.683 to 6.000) |
| Cycle 3 | 3.025 (0.783 to 7.033) | 2.050 (0.700 to 19.783) |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ug/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 5.899 ± 53.3 | 4.048 ± 130.9 |
| Cycle 3 | 12.551 ± 35.9 | 7.846 ± 133.1 |
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe. For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1. Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 551.3 (503.4 to 689.5) | 505.8 (72.3 to 720.7) |
| Cycle 3 | 501.6 (359.9 to 529.4) | 503.0 (213.4 to 528.3) |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| h*ng/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 264.5 ± 57.1 | 147.7 ± 76.3 |
| Cycle 3 | 126.8 ± 42.1 | 112.2 ± 53.6 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours. Outcome data are reported only for AUC over 0-168 hours.
| h*ng/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 248.0 ± 56.8 | 98.9 ± 46.1 |
| Cycle 3 | 93.8 ± 38.5 | 108.7 ± 70.5 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
| ng/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 Day 1 | 0.66 ± 174.5 | 0.35 ± 113.1 |
| Cycle 3 Day 1 | 0.44 ± 34.2 | 0.35 ± 71.8 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| ng/mL | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 3.09 ± 46.1 | 0.93 ± 97.6 |
| Cycle 3 | 0.83 ± 30.8 | 0.68 ± 51.9 |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 23.833 (0.750 to 64.283) | 24.000 (22.017 to 50.700) |
| Cycle 3 | 24.333 (8.033 to 43.000) | 12.425 (4.000 to 22.667) |
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
| Hour | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|
| Cycle 1 | 167.5 (160.4 to 328.8) | 335.5 (24.4 to 526.5) |
| Cycle 3 | 347.3 (334.5 to 502.5) | 332.0 (213.4 to 504.8) |
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
| Millimeters of mercury (mmHg) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| DBP, Baseline (Day 1) | 72.5 ± 9.45 | 70.9 ± 10.20 | 77.8 ± 13.57 | 64.4 ± 5.55 | 74.8 ± 8.86 |
| DBP, CFB to Cycle 1 Day 1, 15 MINS AFTER SOI | -3.6 ± 8.02 | -4.2 ± 8.70 | 1.3 ± 2.87 | 1.6 ± 1.95 | -5.4 ± 7.04 |
| DBP, CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI | 0.2 ± 10.21 | -4.1 ± 7.03 | -2.8 ± 2.75 | 3.2 ± 2.59 | -7.6 ± 5.80 |
| DBP, CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI | 0.8 ± 12.06 | -2.9 ± 10.29 | -1.3 ± 5.19 | 2.0 ± 2.92 | -3.6 ± 6.09 |
| DBP, CFB to Cycle 2 Day 1, PRE-INFUSION | 3.6 ± 8.23 | -5.6 ± 13.67 | 0.7 ± 0.58 | 8.4 ± 6.88 | -2.0 ± 9.57 |
| DBP, CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI | -0.6 ± 7.88 | -5.5 ± 14.81 | 1.3 ± 2.52 | 11.0 ± 7.62 | -6.6 ± 2.97 |
| DBP, CFB to Cycle 3 Day 1, PRE-INFUSION | -5.3 ± 11.15 | 0.8 ± 15.51 | 2.0 ± 1.41 | 9.5 ± 9.11 | 1.4 ± 10.15 |
| DBP, CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI | -7.3 ± 9.46 | 1.0 ± 11.73 | 5.0 ± 1.41 | 5.0 ± 6.98 | -6.8 ± 12.07 |
| DBP, CFB to Cycle 4 Day 1, PRE-INFUSION | -1.0 ± 2.65 | -2.0 ± 17.44 | 1.5 ± 0.71 | 13.8 ± 9.81 | -5.8 ± 9.41 |
| DBP CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI | -2.3 ± 4.62 | 2.0 ± 17.69 | 3.0 ± 2.83 | 13.5 ± 9.15 | -9.4 ± 7.40 |
| DBP, CFB to Cycle 5 Day 1, PRE-INFUSION | -3.7 ± 10.02 | 9.7 ± 31.01 | 2.0 ± NA | 6.0 ± 7.16 | -1.8 ± 7.63 |
| DBP, CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI | -2.0 ± 10.44 | 11.3 ± 23.46 | 3.0 ± NA | 7.0 ± 6.48 | -5.2 ± 3.27 |
| DBP, CFB to Cycle 6 Day 1, PRE-INFUSION | -2.3 ± 10.07 | -8.5 ± 16.26 | -2.0 ± NA | 13.3 ± 12.42 | -6.0 ± 5.15 |
| DBP, CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI | 0.0 ± 10.58 | 11.5 ± 9.19 | 2.0 ± NA | 9.5 ± 12.40 | -7.3 ± 9.22 |
| DBP, CFB to Cycle 7 Day 1, PRE-INFUSION | 0.7 ± 6.66 | -0.5 ± 4.95 | 2.0 ± NA | 17.5 ± 9.19 | -4.5 ± 4.95 |
| DBP, CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI | 2.0 ± 1.73 | -4.0 ± 7.07 | 0.0 ± NA | 20.0 ± 5.66 | -1.0 ± 1.41 |
| DBP, CFB to Cycle 8 Day 1, PRE-INFUSION | -1.0 ± 12.49 | -6.5 ± 13.44 | 1.0 ± NA | 14.0 ± NA | -7.0 ± NA |
| DBP, CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI | -5.7 ± 7.02 | -6.5 ± 14.85 | 2.0 ± NA | 21.0 ± NA | -1.0 ± NA |
| DBP, CFB to Cycle 9 Day 1, PRE-INFUSION | -10.0 ± NA | 3.0 ± NA | 0.0 ± NA | 11.0 ± NA | -3.0 ± NA |
| DBP, CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI | -7.0 ± NA | 4.0 ± NA | 3.0 ± NA | 25.0 ± NA | -8.0 ± NA |
| DBP, CFB to Cycle 10 Day 1, PRE-INFUSION | -10.0 ± NA | 7.0 ± NA | 4.0 ± NA | 17.0 ± NA | -4.0 ± NA |
| DBP, CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI | -11.0 ± NA | 6.0 ± NA | 2.0 ± NA | 15.0 ± NA | -7.0 ± NA |
| DBP, CFB to Cycle 11 Day 1, PRE-INFUSION | -7.0 ± NA | 7.0 ± NA | 1.0 ± NA | 3.0 ± NA | -1.0 ± NA |
| DBP, CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI | -7.0 ± NA | 5.0 ± NA | 5.0 ± NA | 2.0 ± NA | -7.0 ± NA |
| DBP, CFB to Cycle 12 Day 1, PRE-INFUSION | -13.0 ± NA | 1.0 ± NA | -2.0 ± NA | -4.0 ± NA | 6.0 ± NA |
| DBP, CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI | -12.0 ± NA | 3.0 ± NA | 2.0 ± NA | -3.0 ± NA | -2.0 ± NA |
| DBP, CFB to Cycle 13 Day 1, PRE-INFUSION | -17.0 ± NA | 1.0 ± NA | 5.0 ± NA | 34.0 ± NA | 6.0 ± NA |
| DBP, CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI | -25.0 ± NA | 5.0 ± NA | 5.0 ± NA | 25.0 ± NA | 9.0 ± NA |
| DBP, CFB to Cycle 14 Day 1, PRE-INFUSION | -15.0 ± NA | 0.0 ± NA | -1.0 ± NA | 3.0 ± NA | -4.0 ± NA |
| DBP, CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI | -20.0 ± NA | -2.0 ± NA | 4.0 ± NA | -3.0 ± NA | -7.0 ± NA |
| DBP, CFB to Cycle 15 Day 1, PRE-INFUSION | -5.0 ± NA | 0.0 ± NA | -1.0 ± NA | 11.0 ± NA | -7.0 ± NA |
| DBP, CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI | -6.0 ± NA | -1.0 ± NA | 2.0 ± NA | 9.0 ± NA | -15.0 ± NA |
| DBP, CFB to Cycle 16 Day 1, PRE-INFUSION | -15.0 ± NA | 0.0 ± NA | 0.0 ± NA | 7.0 ± NA | -8.0 ± NA |
| DBP, CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI | -10.0 ± NA | 2.0 ± NA | 5.0 ± NA | 2.0 ± NA | -14.0 ± NA |
| DBP, CFB to Cycle 17 Day 1, PRE-INFUSION | -5.0 ± NA | 1.0 ± NA | 2.0 ± NA | 0.0 ± NA | -1.0 ± NA |
| DBP, CFB to Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI | -13.0 ± NA | 5.0 ± NA | 5.0 ± NA | 1.0 ± NA | -4.0 ± NA |
| DBP, CFB to Cycle 18 Day 1, PRE-INFUSION | -15.0 ± NA | -2.0 ± NA | 1.0 ± NA | 7.0 ± NA | -8.0 ± NA |
| DBP, CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI | -5.0 ± NA | 2.0 ± NA | 3.0 ± NA | 1.0 ± NA | -5.0 ± NA |
| DBP, CFB to Cycle 19 Day 1, PRE-INFUSION | -17.0 ± NA | 1.0 ± NA | 3.0 ± NA | 5.0 ± NA | — |
| DBP, CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI | -15.0 ± NA | 6.0 ± NA | 6.0 ± NA | 9.0 ± NA | — |
| DBP, CFB to Cycle 20 Day 1, PRE-INFUSION | -12.0 ± NA | — | — | 7.0 ± NA | — |
| DBP, CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI | -15.0 ± NA | — | — | 9.0 ± NA | — |
| DBP, CFB to Cycle 21 Day 1, PRE-INFUSION | -7.0 ± NA | — | — | — | — |
| DBP, CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI | -7.0 ± NA | — | — | — | — |
| DBP, CFB to Cycle 22 Day 1, PRE-INFUSION | -10.0 ± NA | — | — | — | — |
| DBP, CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI | -5.0 ± NA | — | — | — | — |
| DBP, CFB to Cycle 23 Day 1, PRE-INFUSION | -10.0 ± NA | — | — | — | — |
| DBP, CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI | 0.0 ± NA | — | — | — | — |
| DBP, CFB to End of Treatment (Up to 236 weeks) | -4.5 ± 10.79 | -2.0 ± 12.22 | 7.0 ± NA | 4.0 ± 9.90 | — |
| SBP, Baseline (Day 1) | 120.0 ± 6.99 | 129.9 ± 21.32 | 116.8 ± 8.42 | 121.0 ± 5.29 | 121.9 ± 17.50 |
| SBP, CFB to Cycle 1 Day 1, 15 MINS AFTER SOI | -2.8 ± 8.75 | -2.8 ± 17.04 | 3.8 ± 4.19 | 15.8 ± 15.94 | 1.9 ± 1.95 |
| SBP, CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI | 0.9 ± 11.24 | -1.7 ± 14.94 | 5.0 ± 7.12 | 10.0 ± 15.44 | 0.7 ± 3.73 |
| SBP, CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI | -0.6 ± 11.04 | -3.1 ± 18.61 | 6.0 ± 6.06 | 11.4 ± 14.36 | 2.8 ± 5.63 |
| SBP, CFB to Cycle 2 Day 1, PRE-INFUSION | 1.6 ± 14.43 | -2.0 ± 19.76 | 3.7 ± 3.06 | 27.0 ± 24.27 | 9.0 ± 17.47 |
| SBP, CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI | -0.9 ± 5.46 | -4.1 ± 16.21 | 3.7 ± 1.53 | 22.0 ± 19.69 | 2.8 ± 7.29 |
| SBP, CFB to Cycle 3 Day 1, PRE-INFUSION | -5.8 ± 4.99 | 2.4 ± 16.38 | 6.5 ± 6.36 | 22.8 ± 16.88 | 10.0 ± 11.72 |
| SBP, CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI | -3.8 ± 5.44 | -0.6 ± 19.96 | 2.5 ± 2.12 | 24.5 ± 18.52 | 9.0 ± 16.84 |
| SBP, CFB to Cycle 4 Day 1, PRE-INFUSION | -0.3 ± 2.52 | -9.0 ± 22.34 | 0.0 ± 2.83 | 10.0 ± 15.81 | 7.0 ± 9.70 |
| SBP, CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI | -6.0 ± 4.36 | -9.0 ± 25.71 | -0.5 ± 9.19 | 25.5 ± 25.28 | 4.0 ± 3.94 |
| SBP, CFB to Cycle 5 Day 1, PRE-INFUSION | 0.3 ± 5.77 | 9.7 ± 24.11 | 7.0 ± NA | 11.8 ± 16.94 | 13.8 ± 13.48 |
| SBP, CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI | 5.7 ± 10.69 | -0.7 ± 34.24 | 6.0 ± NA | 13.3 ± 17.73 | 8.6 ± 10.14 |
| SBP, CFB to Cycle 6 Day 1, PRE-INFUSION | -4.3 ± 1.53 | -10.0 ± 12.73 | 8.0 ± NA | 9.3 ± 25.40 | 0.6 ± 15.52 |
| SBP, CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI | 4.7 ± 12.42 | -11.0 ± 15.56 | 6.0 ± NA | 9.8 ± 25.62 | 12.3 ± 13.72 |
| SBP, CFB to Cycle 7 Day 1, PRE-INFUSION | 3.3 ± 10.12 | -6.0 ± 2.83 | 6.0 ± NA | 23.5 ± 30.41 | -7.0 ± 1.41 |
| SBP, CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI | 3.0 ± 8.72 | -20.5 ± 26.16 | 10.0 ± NA | 26.0 ± 48.08 | -9.0 ± 11.31 |
| SBP, CFB to Cycle 8 Day 1, PRE-INFUSION | -2.3 ± 4.04 | -8.5 ± 12.02 | 1.0 ± NA | 30.0 ± NA | 0.0 ± NA |
| SBP, CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI | -6.3 ± 5.86 | -11.0 ± 19.80 | 0.0 ± NA | 75.0 ± NA | -1.0 ± NA |
| SBP, CFB to Cycle 9 Day 1, PRE-INFUSION | -3.0 ± NA | 3.0 ± NA | 3.0 ± NA | 54.0 ± NA | 14.0 ± NA |
| SBP, CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI | 3.0 ± NA | 5.0 ± NA | 5.0 ± NA | 80.0 ± NA | 4.0 ± NA |
| SBP, CFB to Cycle 10 Day 1, PRE-INFUSION | -3.0 ± NA | 5.0 ± NA | 9.0 ± NA | 56.0 ± NA | 0.0 ± NA |
| SBP, CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI | -2.0 ± NA | 3.0 ± NA | 12.0 ± NA | 52.0 ± NA | 4.0 ± NA |
| SBP, CFB to Cycle 11 Day 1, PRE-INFUSION | -13.0 ± NA | -4.0 ± NA | 2.0 ± NA | 18.0 ± NA | 20.0 ± NA |
| SBP, CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI | -5.0 ± NA | 0.0 ± NA | 3.0 ± NA | 30.0 ± NA | 15.0 ± NA |
| SBP, CFB to Cycle 12 Day 1, PRE-INFUSION | -13.0 ± NA | 5.0 ± NA | 8.0 ± NA | 15.0 ± NA | 5.0 ± NA |
| SBP, CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI | -8.0 ± NA | 4.0 ± NA | 12.0 ± NA | 17.0 ± NA | 3.0 ± NA |
| SBP, CFB to Cycle 13 Day 1, PRE-INFUSION | 5.0 ± NA | -2.0 ± NA | 7.0 ± NA | 42.0 ± NA | 6.0 ± NA |
| SBP, CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI | -5.0 ± NA | -1.0 ± NA | 6.0 ± NA | 44.0 ± NA | 4.0 ± NA |
| SBP, CFB to Cycle 14 Day 1, PRE-INFUSION | -3.0 ± NA | -4.0 ± NA | 12.0 ± NA | 19.0 ± NA | 0.0 ± NA |
| SBP, CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI | 0.0 ± NA | 0.0 ± NA | 13.0 ± NA | 18.0 ± NA | 4.0 ± NA |
| SBP, CFB to Cycle 15 Day 1, PRE-INFUSION | 7.0 ± NA | 5.0 ± NA | 7.0 ± NA | 41.0 ± NA | 0.0 ± NA |
| SBP, CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI | 6.0 ± NA | 4.0 ± NA | 9.0 ± NA | 42.0 ± NA | 4.0 ± NA |
| SBP, CFB to Cycle 16 Day 1, PRE-INFUSION | -3.0 ± NA | 4.0 ± NA | 6.0 ± NA | 41.0 ± NA | -6.0 ± NA |
| SBP, CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI | 2.0 ± NA | 6.0 ± NA | 9.0 ± NA | 31.0 ± NA | 4.0 ± NA |
| SBP, Cycle 17 Day 1, PRE-INFUSION | -3.0 ± NA | 4.0 ± NA | 3.0 ± NA | 23.0 ± NA | 25.0 ± NA |
| SBP, Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI | -5.0 ± NA | 2.0 ± NA | 8.0 ± NA | 35.0 ± NA | 23.0 ± NA |
| SBP, CFB to Cycle 18 Day 1, PRE-INFUSION | -3.0 ± NA | -3.0 ± NA | 4.0 ± NA | 48.0 ± NA | 0.0 ± NA |
| SBP, CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI | -3.0 ± NA | 1.0 ± NA | 8.0 ± NA | 33.0 ± NA | 15.0 ± NA |
| SBP, CFB to Cycle 19 Day 1, PRE-INFUSION | -5.0 ± NA | 6.0 ± NA | 2.0 ± NA | 28.0 ± NA | — |
| SBP, CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI | -3.0 ± NA | 8.0 ± NA | 7.0 ± NA | 48.0 ± NA | — |
| SBP, CFB to Cycle 20 Day 1, PRE-INFUSION | 4.0 ± NA | — | — | 50.0 ± NA | — |
| SBP, CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI | 3.0 ± NA | — | — | 48.0 ± NA | — |
| SBP, CFB to Cycle 21 Day 1, PRE-INFUSION | 26.0 ± NA | — | — | — | — |
| SBP, CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI | 12.0 ± NA | — | — | — | — |
| SBP, CFB to Cycle 22 Day 1, PRE-INFUSION | -1.0 ± NA | — | — | — | — |
| SBP, CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI | 12.0 ± NA | — | — | — | — |
| SBP, CFB to Cycle 23 Day 1, PRE-INFUSION | 11.0 ± NA | — | — | — | — |
| SBP, CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI | 9.0 ± NA | — | — | — | — |
| SBP, CFB to End of Treatment (Up to 236 weeks) | -2.8 ± 12.79 | -5.9 ± 15.39 | 1.0 ± NA | 31.0 ± 29.70 | — |
Heart rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated as post-dose visit value minus Baseline value.
| Beats per minute | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Baseline (Day 1) | 77.2 ± 14.67 | 74.9 ± 15.34 | 71.8 ± 4.57 | 69.0 ± 11.05 | 67.4 ± 6.78 |
| CFB to Cycle 1 Day 1, 15 MINS AFTER SOI | -1.3 ± 3.65 | -4.0 ± 6.22 | 2.0 ± 2.94 | 1.2 ± 5.45 | 2.3 ± 2.87 |
| CFB to Cycle 1 Day 1, WITHIN 15 MINS AFTER EOI | -1.1 ± 6.03 | -0.9 ± 4.04 | 4.3 ± 7.41 | 1.8 ± 7.19 | 2.1 ± 2.27 |
| CFB to Cycle 1 Day 1, 1 HOUR AFTER EOI | 3.0 ± 5.72 | -1.0 ± 4.30 | 4.8 ± 10.37 | -1.2 ± 6.91 | 0.9 ± 3.56 |
| CFB to Cycle 2 Day 1, PRE-INFUSION | 1.2 ± 10.03 | -5.0 ± 5.50 | 1.3 ± 9.29 | -0.2 ± 9.15 | 1.2 ± 7.96 |
| CFB to Cycle 2 Day 1, WITHIN 15 MINS AFTER EOI | -2.2 ± 13.34 | -3.8 ± 7.67 | -0.3 ± 7.37 | -1.0 ± 10.49 | 6.4 ± 8.53 |
| CFB to Cycle 3 Day 1, PRE-INFUSION | -12.3 ± 7.85 | -2.4 ± 11.48 | 7.5 ± 9.19 | 5.3 ± 19.05 | 2.9 ± 9.12 |
| CFB to Cycle 3 Day 1, WITHIN 15 MINS AFTER EOI | -9.0 ± 9.45 | 0.6 ± 13.50 | 4.5 ± 6.36 | -5.0 ± 7.79 | 5.8 ± 10.23 |
| CFB to Cycle 4 Day 1, PRE-INFUSION | 0.0 ± 6.00 | -12.3 ± 25.74 | 5.5 ± 14.85 | -6.5 ± 11.47 | 4.0 ± 5.37 |
| CFB to Cycle 4 Day 1, WITHIN 15 MINS AFTER EOI | -1.3 ± 9.07 | -15.7 ± 22.94 | 1.0 ± 11.31 | -8.5 ± 12.87 | 6.0 ± 5.52 |
| CFB to Cycle 5 Day 1, PRE-INFUSION | -3.7 ± 19.14 | -3.3 ± 9.29 | 0.0 ± NA | -5.8 ± 8.96 | 5.7 ± 10.65 |
| CFB to Cycle 5 Day 1, WITHIN 15 MINS AFTER EOI | -6.0 ± 11.14 | -5.7 ± 9.07 | -2.0 ± NA | -5.0 ± 9.24 | 4.2 ± 3.83 |
| CFB to Cycle 6 Day 1, PRE-INFUSION | -6.0 ± 13.11 | 8.5 ± 7.78 | -3.0 ± NA | -0.3 ± 7.41 | 6.2 ± 7.92 |
| CFB to Cycle 6 Day 1, WITHIN 15 MINS AFTER EOI | -7.7 ± 9.61 | 3.5 ± 3.54 | -4.0 ± NA | 1.8 ± 7.27 | 4.5 ± 7.42 |
| CFB to Cycle 7 Day 1, PRE-INFUSION | -5.3 ± 7.09 | 3.5 ± 2.12 | -8.0 ± NA | -1.5 ± 6.36 | 5.5 ± 0.71 |
| CFB to Cycle 7 Day 1, WITHIN 15 MINS AFTER EOI | -8.3 ± 12.86 | 2.5 ± 2.12 | -3.0 ± NA | 2.0 ± 9.90 | 6.5 ± 0.71 |
| CFB to Cycle 8 Day 1, PRE-INFUSION | -9.7 ± 12.58 | 14.5 ± 16.26 | -4.0 ± NA | -17.0 ± NA | 6.0 ± NA |
| CFB to Cycle 8 Day 1, WITHIN 15 MINS AFTER EOI | -11.3 ± 9.29 | 15.0 ± 18.38 | -2.0 ± NA | -18.0 ± NA | 8.0 ± NA |
| CFB to Cycle 9 Day 1, PRE-INFUSION | -20.0 ± NA | 5.0 ± NA | -8.0 ± NA | -22.0 ± NA | 10.0 ± NA |
| CFB to Cycle 9 Day 1, WITHIN 15 MINS AFTER EOI | -22.0 ± NA | 4.0 ± NA | -10.0 ± NA | -17.0 ± NA | 12.0 ± NA |
| CFB to Cycle 10 Day 1, PRE-INFUSION | -23.0 ± NA | 6.0 ± NA | -5.0 ± NA | -17.0 ± NA | 5.0 ± NA |
| CFB to Cycle 10 Day 1, WITHIN 15 MINS AFTER EOI | -24.0 ± NA | 4.0 ± NA | -2.0 ± NA | -16.0 ± NA | 0.0 ± NA |
| CFB to Cycle 11 Day 1, PRE-INFUSION | -9.0 ± NA | 7.0 ± NA | -4.0 ± NA | -12.0 ± NA | 0.0 ± NA |
| CFB to Cycle 11 Day 1, WITHIN 15 MINS AFTER EOI | -20.0 ± NA | 5.0 ± NA | -8.0 ± NA | -10.0 ± NA | 1.0 ± NA |
| CFB to Cycle 12 Day 1, PRE-INFUSION | -10.0 ± NA | 2.0 ± NA | 1.0 ± NA | -2.0 ± NA | 4.0 ± NA |
| CFB to Cycle 12 Day 1, WITHIN 15 MINS AFTER EOI | -9.0 ± NA | 7.0 ± NA | 2.0 ± NA | -5.0 ± NA | 2.0 ± NA |
| CFB to Cycle 13 Day 1, PRE-INFUSION | -22.0 ± NA | 3.0 ± NA | -2.0 ± NA | -6.0 ± NA | 4.0 ± NA |
| CFB to Cycle 13 Day 1, WITHIN 15 MINS AFTER EOI | -33.0 ± NA | 4.0 ± NA | 1.0 ± NA | 2.0 ± NA | 2.0 ± NA |
| CFB to Cycle 14 Day 1, PRE-INFUSION | -28.0 ± NA | 3.0 ± NA | -8.0 ± NA | -6.0 ± NA | 6.0 ± NA |
| CFB to Cycle 14 Day 1, WITHIN 15 MINS AFTER EOI | -30.0 ± NA | 4.0 ± NA | -6.0 ± NA | -5.0 ± NA | -2.0 ± NA |
| CFB to Cycle 15 Day 1, PRE-INFUSION | -24.0 ± NA | 10.0 ± NA | 0.0 ± NA | -15.0 ± NA | 0.0 ± NA |
| CFB to Cycle 15 Day 1, WITHIN 15 MINS AFTER EOI | -24.0 ± NA | 8.0 ± NA | -1.0 ± NA | -14.0 ± NA | -1.0 ± NA |
| CFB to Cycle 16 Day 1, PRE-INFUSION | -30.0 ± NA | 6.0 ± NA | -5.0 ± NA | -17.0 ± NA | -2.0 ± NA |
| CFB to Cycle 16 Day 1, WITHIN 15 MINS AFTER EOI | -28.0 ± NA | 2.0 ± NA | -3.0 ± NA | -11.0 ± NA | 2.0 ± NA |
| CFB to Cycle 17 Day 1, PRE-INFUSION | -30.0 ± NA | 3.0 ± NA | -2.0 ± NA | -3.0 ± NA | 0.0 ± NA |
| CFB to Cycle 17 Day 1, WITHIN 15 MINS AFTER EOI | -28.0 ± NA | 2.0 ± NA | 0.0 ± NA | -3.0 ± NA | 7.0 ± NA |
| CFB to Cycle 18 Day 1, PRE-INFUSION | -40.0 ± NA | 5.0 ± NA | -1.0 ± NA | -9.0 ± NA | -4.0 ± NA |
| CFB to Cycle 18 Day 1, WITHIN 15 MINS AFTER EOI | -38.0 ± NA | 6.0 ± NA | -2.0 ± NA | -1.0 ± NA | 11.0 ± NA |
| CFB to Cycle 19 Day 1, PRE-INFUSION | -38.0 ± NA | 6.0 ± NA | 3.0 ± NA | -8.0 ± NA | — |
| CFB to Cycle 19 Day 1, WITHIN 15 MINS AFTER EOI | -40.0 ± NA | 9.0 ± NA | 2.0 ± NA | -2.0 ± NA | — |
| CFB to Cycle 20 Day 1, PRE-INFUSION | -20.0 ± NA | — | — | 1.0 ± NA | — |
| CFB to Cycle 20 Day 1, WITHIN 15 MINS AFTER EOI | -17.0 ± NA | — | — | -2.0 ± NA | — |
| CFB to Cycle 21 Day 1, PRE-INFUSION | -16.0 ± NA | — | — | — | — |
| CFB to Cycle 21 Day 1, WITHIN 15 MINS AFTER EOI | -34.0 ± NA | — | — | — | — |
| CFB to Cycle 22 Day 1, PRE-INFUSION | -23.0 ± NA | — | — | — | — |
| CFB to Cycle 22 Day 1, WITHIN 15 MINS AFTER EOI | -18.0 ± NA | — | — | — | — |
| CFB to Cycle 23 Day 1, PRE-INFUSION | -19.0 ± NA | — | — | — | — |
| CFB to Cycle 23 Day 1, WITHIN 15 MINS AFTER EOI | -29.0 ± NA | — | — | — | — |
| CFB to End of Treatment (Up to 236 weeks) | 8.8 ± 26.08 | 14.1 ± 10.61 | 3.0 ± NA | 8.0 ± 22.63 | — |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Part 1 and Part 2: Number of Participants With Adverse Events (AEs) | 10 | 9 | 3 | 5 | 8 |
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Anemia, Increase to Grade 3 | 2 | 2 | 1 | 2 | 3 |
| Anemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Eosinophilia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Eosinophilia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Hemoglobin increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count decreased, Increase to Grade 3 | 2 | 1 | 0 | 2 | 1 |
| Lymphocyte count decreased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Lymphocyte count increased, Increase to Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Lymphocyte count increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased, Increase to Grade 3 | 1 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 1 |
| Platelet count decreased, Increase to Grade 3 | 2 | 1 | 0 | 1 | 2 |
| Platelet count decreased, Increase to Grade 4 | 2 | 2 | 0 | 0 | 0 |
| White blood cell decreased, Increase to Grade 3 | 1 | 1 | 0 | 0 | 1 |
| White blood cell decreased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade was defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Alanine aminotransferase (ALT) increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| ALT increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase (ALP) increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| ALP increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Aspartate aminotransferase (AST) increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| AST increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood bilirubin increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Creatine kinase (CPK) increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| CPK increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease eGFR, Increase to Grade 3 | 0 | 1 | 0 | 0 | 0 |
| Chronic Kidney Disease eGFR, Increase to Grade 4 | 0 | 1 | 0 | 0 | 1 |
| Chronic Kidney Disease iGFR, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Chronic Kidney Disease iGFR, Increase to Grade 4 | 1 | 0 | 0 | 0 | 1 |
| Creatinine increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Gamma-glutamyltransferase (GGT) increased, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| GGT increased, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypercalcemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hyperkalemia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 1 |
| Hyperkalemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypermagnesemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypernatremia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia, Increase to Grade 3 | 1 | 0 | 0 | 0 | 0 |
| Hypoalbuminemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypocalcemia, Increase to Grade 4 | 0 | 1 | 0 | 0 | 0 |
| Hypoglycemia, Increase to Grade 3 | 0 | 0 | 0 | 0 | 0 |
| Hypoglycemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 1 |
| Hypomagnesemia, Increase to Grade 3 | 0 | 0 | 0 | 1 | 0 |
| Hypomagnesemia, Increase to Grade 4 | 0 | 0 | 0 | 0 | 0 |
Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline
| Kilogram (Kg) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Baseline (Day 1) | 73.44 ± 19.619 | 68.92 ± 12.143 | 84.03 ± 28.349 | 61.34 ± 15.536 | 68.41 ± 20.296 |
| CFB to Cycle 2 Day 1 | 0.51 ± 2.750 | 0.34 ± 0.870 | -0.43 ± 0.929 | -0.22 ± 1.794 | 0.17 ± 0.695 |
| CFB to Cycle 3 Day 1 | 0.38 ± 0.624 | 0.52 ± 1.099 | -0.15 ± 0.495 | 0.63 ± 1.040 | -0.89 ± 3.302 |
| CFB to Cycle 4 Day 1 | -0.80 ± 3.863 | 1.10 ± 0.173 | -0.75 ± 1.061 | 1.18 ± 1.195 | -0.17 ± 2.967 |
| CFB to Cycle 5 Day 1 | 0.07 ± 2.663 | 1.60 ± 0.656 | 0.50 ± NA | 1.43 ± 1.338 | 0.47 ± 4.575 |
| CFB to Cycle 6 Day 1 | 1.33 ± 3.889 | 1.45 ± 0.778 | -0.80 ± NA | 1.88 ± 4.785 | -2.88 ± 3.664 |
| CFB to Cycle 7 Day 1 | 0.13 ± 2.695 | 2.15 ± 0.212 | -1.20 ± NA | 1.95 ± 1.344 | -2.20 ± 2.970 |
| CFB to Cycle 8 Day 1 | 0.10 ± 3.843 | -0.10 ± 3.394 | -1.40 ± NA | 3.00 ± NA | 0.00 ± NA |
| CFB to Cycle 9 Day 1 | 5.00 ± NA | 2.50 ± NA | -1.50 ± NA | 3.50 ± NA | 0.20 ± NA |
| CFB to Cycle 10 Day 1 | 3.30 ± NA | 2.60 ± NA | -1.60 ± NA | 3.60 ± NA | 0.00 ± NA |
| CFB to Cycle 11 Day 1 | 3.40 ± NA | 2.50 ± NA | -1.70 ± NA | 3.00 ± NA | -0.40 ± NA |
| CFB to Cycle 12 Day 1 | 3.30 ± NA | 2.30 ± NA | -1.70 ± NA | 4.50 ± NA | -0.40 ± NA |
| CFB to Cycle 13 Day 1 | 2.90 ± NA | 2.40 ± NA | -1.80 ± NA | 4.80 ± NA | -0.40 ± NA |
| CFB to Cycle 14 Day 1 | 5.50 ± NA | 2.50 ± NA | -1.60 ± NA | 3.00 ± NA | -0.70 ± NA |
| CFB to Cycle 15 Day 1 | 6.50 ± NA | 2.40 ± NA | -1.40 ± NA | 2.00 ± NA | 0.00 ± NA |
| CFB to Cycle 16 Day 1 | 4.80 ± NA | 2.70 ± NA | -1.50 ± NA | 1.30 ± NA | 0.20 ± NA |
| CFB to Cycle 17 Day 1 | 3.00 ± NA | 2.10 ± NA | -1.60 ± NA | 1.60 ± NA | -0.20 ± NA |
| CFB to Cycle 18 Day 1 | 2.00 ± NA | 2.00 ± NA | -1.80 ± NA | 1.00 ± NA | 0.30 ± NA |
| CFB to Cycle 19 Day 1 | 1.60 ± NA | 2.30 ± NA | -1.70 ± NA | 0.70 ± NA | — |
| CFB to Cycle 20 Day 1 | 0.70 ± NA | — | — | 0.90 ± NA | — |
| CFB to Cycle 21 Day 1 | 1.00 ± NA | — | — | — | — |
| CFB to Cycle 22 Day 1 | 1.00 ± NA | — | — | — | — |
| CFB to Cycle 23 Day 1 | 2.80 ± NA | — | — | — | — |
| CFB to Week 07 | — | 2.50 ± NA | — | — | — |
| CFB to Week 10 | — | 0.00 ± NA | — | — | — |
| CFB to Week 13 | — | -3.00 ± NA | — | — | — |
| CFB to End of Treatment (Up to 236 weeks) | -1.38 ± 4.886 | 0.47 ± 2.856 | 0.00 ± NA | -0.80 ± 1.273 | — |
Urine samples were collected to assess occult blood and protein in urine by dipstick method. Data is presented as "No Change/Decreased" and "Any Increase" that includes Increase to TRACE, Increase to 1+, Increase to 2+ and Increase to 3+ indicating proportional concentrations in the urine sample. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
| Participants | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| Occult Blood — No Change/Decreased | 0 | 0 | 0 | 0 | 0 |
| Occult Blood — Any Increase | 0 | 1 | 0 | 0 | 0 |
| Protein — No Change/Decreased | 3 | 5 | 2 | 4 | 2 |
| Protein — Any Increase | 2 | 3 | 0 | 1 | 0 |
Collected over All-cause mortality, non-serious adverse events (non-SAEs) and SAEs were collected up to approximately 236 weeks. The results presented are based on the data cut-off date of 21 April 2025. Additional safety results will be provided within one year of study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | 2/10 (20%) | 4/10 (40%) | 10/10 (100%) |
| Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | 3/9 (33.3%) | 4/9 (44.4%) | 9/9 (100%) |
| Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | 1/5 (20%) | 3/5 (60%) | 5/5 (100%) |
| Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) | 3/8 (37.5%) | 4/8 (50%) | 8/8 (100%) |
| Event | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/10 | 1/9 | 0/4 | 1/5 | 2/8 |
| Acute kidney injuryRenal and urinary disorders | 0/10 | 1/9 | 1/4 | 0/5 | 0/8 |
| FallInjury, poisoning and procedural complications | 0/10 | 0/9 | 1/4 | 0/5 | 0/8 |
| FractureInjury, poisoning and procedural complications | 0/10 | 0/9 | 1/4 | 0/5 | 0/8 |
| Chronic kidney diseaseRenal and urinary disorders | 0/10 | 2/9 | 0/4 | 0/5 | 0/8 |
| COVID-19Infections and infestations | 1/10 | 0/9 | 0/4 | 1/5 | 0/8 |
| Sudden deathGeneral disorders | 0/10 | 0/9 | 0/4 | 1/5 | 0/8 |
| Humerus fractureInjury, poisoning and procedural complications | 0/10 | 0/9 | 0/4 | 1/5 | 0/8 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/9 | 0/4 | 1/5 | 0/8 |
| Bone painMusculoskeletal and connective tissue disorders | 0/10 | 0/9 | 0/4 | 1/5 | 0/8 |
| Event | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/10 | 1/9 | 1/4 | 4/5 | 2/8 |
| Vision blurredEye disorders | 6/10 | 5/9 | 1/4 | 3/5 | 3/8 |
| Dry eyeEye disorders | 5/10 | 4/9 | 2/4 | 0/5 | 4/8 |
| Eye irritationEye disorders | 5/10 | 3/9 | 1/4 | 1/5 | 3/8 |
| Foreign body sensation in eyesEye disorders | 5/10 | 2/9 | 1/4 | 1/5 | 2/8 |
| ChillsGeneral disorders | 0/10 | 0/9 | 2/4 | 0/5 | 0/8 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/10 | 0/9 | 2/4 | 0/5 | 0/8 |
| Eye painEye disorders | 4/10 | 1/9 | 0/4 | 1/5 | 1/8 |
| AnaemiaBlood and lymphatic system disorders | 4/10 | 1/9 | 1/4 | 2/5 | 2/8 |
| Alanine aminotransferase increasedInvestigations | 1/10 | 0/9 | 0/4 | 2/5 | 1/8 |
| Age, Continuous(YEARS) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) | Total |
|---|---|---|---|---|---|---|
| Mean | 60.3 ± 8.21 | 74.6 ± 6.11 | 67.5 ± 10.79 | 81.4 ± 5.22 | 70.9 ± 6.83 | 69.9 ± 10.00 |
| Sex: Female, Male(Participants) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 1 | 3 | 1 | 2 | 11 |
| Male | 6 | 8 | 1 | 4 | 6 | 25 |
| Race (NIH/OMB)(Participants) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function) | Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function) | Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis) | Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 5 | 2 | 0 | 3 | 1 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 0 | 4 | 7 |
| White | 4 | 5 | 4 | 2 | 3 | 18 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Ran from Oct 2020 to primary completion in Apr 2025, 54 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 54 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin